Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.

Tay will receive $50m in upfront and milestone payments, along with royalties.

VYNE will have the exclusive rights to develop the oral inhibitor, TAY-B2 (VYN202).

TAY-B2 has previously shown its potential for anti-inflammatory and anti-fibrotic effects in preclinical models. This has enabled VYNE to exercise the option to advance its development to treat key immuno-inflammatory conditions with high unmet requirements.

The most recent deal comes after Tay licensed TAY-B1 to VYNE in 2021.

The out-licensing of both BET inhibitors of Tay means that the firm will receive potential milestone revenues of more than $65m, in addition to up to 10% of tiered royalty payments of net sales per year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tay Therapeutics CEO Dr Andrew Woodland stated: “The second deal with VYNE is the culmination of two years of discovery and development of BET inhibitors with differentiated selectivity and safety profiles.

“I am delighted for the Tay team and consider VYNE ideally placed to continue developing and maximising the value of the BET inhibitor projects.

“This deal further validates Tay’s business model of growing organically using revenues to support development activities, with around £6m received in upfront and milestone payments from the VYNE collaboration to date.”